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ABSTRACT
Introduction: Using the Indian and rest of
world (ROW) injection technique questionnaire
(ITQ) data, we address key insulin injection
complications.
Methods: In 2015 we conducted an ITQ survey
throughout India involving 1011 patients.
Indian values were compared with those from
41 other countries participating in the ITQ,
known here as ROW.
Results: More than a quarter of Indian insulin
users described lesions consistent with lipohy-
pertrophy (LH) at their injection sites and
approximately 1 in 5 were found to have LH by
the examining nurse (using visual inspection
and palpation). Just over half of Indian injectors
report having pain on injection. Of these, 4 out
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of 5 report having painful injections only sev-
eral times a month or year (i.e., not with every
injection). Doctors and diabetes educators in
India (as opposed to nurses) have a larger role in
teaching patients how to inject than they do in
ROW. Despite this specialized approach, a very
high percentage of patients report that they
have not been trained (at least cannot remem-
ber being trained) in a wide range of essential
injection topics. Only about 30% of Indian
injectors get their sites checked at least annu-
ally, with nearly a third only having sites
checked when they specifically complained and
nearly 4 out of 10 never having had their sites
checked.
Conclusion: Indian HCPs can clearly do a bet-
ter job covering all the vital topics essential to
proper injection habits.




In a previous paper we introduced the Indian
injection technique questionnaire (ITQ) survey
patient population and injecting practice [1]. In
conjunction with the results, we gave evi-
dence-based Indian best practice recommenda-
tions. Here we use the same approach for
injecting complications.
METHODS
Our previous paper [1] described the methods,
materials, centers, and patients who partici-
pated in the study.
All procedures followed were in accordance
with the ethical standards of the Indian Council
of Medical Research, the responsible committee
on human experimentation (institutional and
national), and the Helsinki Declaration of 1964,
as revised in 2013. Informed consent was




Patients were asked: ‘‘Do you have any swelling
or lumps under the skin at your usual injection
sites that have been there for some time (weeks,
months, or years)?’’ Table 1 gives the results for
both the patients’ answers and the nurses’
examination of all patient injecting sites.
Indian results are given beside rest of world
(ROW). The latter constitute the values from the
41 other ITQ participating countries combined
(excluding India).
Nurses examined each of the patient’s
injection sites both visually and by palpation
and reported any LH (Table 2). Percentages for
both visual and palpated LH in India were







As per patient report 25.9 29.2
As per nurse examination 21.9 31.8
ROW (rest of world) constitutes the values from the 41
other ITQ participating countries combined (excluding
India)








Abdomen Visual 6.8 17.3
Palpation 9.3 21.1
Thigh Visual 6.9 9.8
Palpation 8.7 11.2
Buttocks Visual 3.4 2.1
Palpation 0.0 2.8
Arm Visual 9.4 11.2
Palpation 10.1 13.4
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slightly lower than in ROW.When nurses found
LH they were asked to measure the lesions along
their longest dimension in millimeters. Table 3
shows that LH size in Indian patients was on
average slightly lower in the abdomen and
thigh and slightly higher in the arm. Whenever
nurses found LH they asked the patient if they
were still injecting into it and 18.9% of Indian
patients said yes. They were then asked how
often they did so (Table 4). Patients who injec-
ted into LH were also asked why they did so
(Table 5). More than half of Indian patients
answered ‘Don’t know’ to that question.
The worldwide ITQ data [2, 3] showed a
strong association between the presence of LH
and the total daily dose (TDD) of insulin. Over
10 IU of insulin on average was consumed in
the LH? population vs LH-. In T2DM patients,
this average TDD difference is 13.5 IU. In T1DM
patients, the average TDD difference is 5.4 IU.
The presence of LH is associated with higher
HbA1c values, an average difference of 0.55. The
worldwide data also showed that LH is associ-
ated with incorrect rotation of injection sites,
using smaller injecting zones, more years on
insulin, and reusing pen needles. The higher the
number of times the needle is reused, the more
frequently reported LH is.
We defined ‘‘hypoglycemia’’ as the occur-
rence of at least one symptom of low sugar (e.g.,
palpitations, tiredness, sweating, strong hunger,
dizziness, tremor) and a confirmed blood glu-
cose meter reading of no greater than 60 mg/dL
(3.3 mM/L). We defined ‘‘frequent unexplained
hypoglycemia’’ as hypoglycemia occurring one
or more times weekly in the absence of a
definable precipitating event such as a change
in medication, diet, or activity. We defined
‘‘glycemic variability’’ as the presence of blood
glucose oscillations from less than 60 mg/dL
(3.3 mM/L) to more than 250 mg/dL (13.9 mM/
L) at least three times a week in an unpre-
dictable and unexplained fashion and evidence
of such a pattern for at least the previous
6 months.
Nurses were asked to review the records of
each subject in the ITQ and assess how many
qualified as having ‘‘frequent unexplained
hypoglycemia’’ and ‘‘glucose variability’’.
Approximately 1 out of 4 Indian insulin injec-
tors had frequent unexpected hypoglycemia
and more than 1 out of 3 had glucose variability
(Table 6). These findings are proportionally
Table 3 Size of nurse-measured lipohypertrophy for








N India N ROW
Abdominal 39.1 44.7 62 1258
Thigh 40.4 42.0 27 460
Arm 39.0 35.5 21 372
Table 4 Frequency of injection into lipohypertrophy in





Every injection 6.8 16.7
Frequently (daily) 28.8 39.5
Occasionally (weekly) 44.1 30.3
Seldom (monthly) 20.3 13.5
Table 5 Reasons patients report injecting into lipohyper-





It is convenient 4.2 16.3
It is less painful 13.3 22.3
Just a habit 29.7 34.9
Do not know 52.8 26.5
Table 6 Frequency of unexpected hypoglycemia and glu-
cose variability in Indian patients
% India % ROW N India N ROW
Unexpected hypoglycemia
Yes 24.1 19.4 236 1580
No 75.9 80.6 745 6558
Glucose variability
Yes 37.3 35.4 369 2872
No 62.7 64.6 621 5251
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similar in India to ROW. In general, LH is
associated with higher rates of unexplained
hypoglycemia and higher rates of glycemic
variability as well as more frequent diabetic
ketoacidosis (DKA). Nurses also assessed injec-
tion sites for lipoatrophy and redness, and
Table 7 gives the results for India and ROW.
Rotation of Injecting Sites
Correct site rotation is defined as always injecting
at least 1 cm from a previous injection. World-
wide ITQ data shows that patients who rotate
correctly tend to have less hyperglycemia, less
LH, less unexplained hyperglycemia, and less
glucose variability. (Data not shown for the
aforementioned, but all differences were signif-
icant to a p\0.05.) HbA1c is lower in those who
correctly rotate by an average of 0.53. Correct
rotation is also associated with lower TDD by an
average of 4.7 IU. Table 8 shows that 68.1% of
Indian injectors were found to correctly rotate
site, a value similar to that in ROW.
Bleeding, Bruising, Pain, and Leakage
Indian patients were asked if they ever observed
bleeding or bruising from their injection sites
and 41.4% said they did. They were then asked
about the frequency and only 0.9% said it was
‘‘always’’, 7.8% said ‘‘often’’ (several times a
week), 53.6% said ‘‘sometimes’’ (several times a
month), and 37.7% said it was ‘‘almost never’’
(several times a year).
We found that just over half of Indian
injectors report having pain on injection. Of
these, 4 out of 5 report having painful injec-
tions only several times a month or year (i.e.,
not with every injection). Pain seems also to be
commonly associated with bleeding. Approxi-
mately 1 out of 5 Indian patients report leakage
of insulin from the skin. Of these, approxi-
mately 85% say it occurs rarely (several times a
month or a year).
Indian patients were asked who gave them
their injection training. Table 9 makes clear that
doctors and diabetes educators in India have a
larger role in teaching patients how to inject
than they do in ROW. Pharmacists and industry
representatives are also more engaged in India
than ROW. Health care in India is often deliv-
ered in very rapid physician visits and diabetes
care is no exception; it is common for a physi-
cian to see from 50 to 100 outpatients in a day.
Injection training is still considered the prevue
of the doctor in India.
Table 7 Nurse-reported lipoatrophy and redness in
Indian and ROW patients




Abdomen Lipoatrophy 0.4 0.6
Redness 5.7 3.3
Thigh Lipoatrophy 1.2 0.5
Redness 5.4 2.8
Buttocks Lipoatrophy 0.0 0.2
Redness 3.4 0.4
Arm Lipoatrophy 0.7 0.4
Redness 2.4 3.6






Practice correct rotation 68.1 71.0
Table 9 Professional who gave patient injection training




General nurse 13.9 22.9
Diabetes nurse 15.7 46.7
Diabetes educator 23.4 12.3
Doctor (general practitioner) 15.3 5.1
Doctor (diabetes specialist) 17.1 10.0
Pharmacist 7.8 2.0




Indian patients were asked how often their
injection sites were checked by their HCP.
Table 10 shows that in India, as in ROW, the
goal of checking injection sites at least once a
year is not being met for the majority of
patients. Patients were asked when they last
received instruction or advice on injections.
Table 11 shows that India is actually performing
slightly better than ROW in giving advice
within the last year.
Indian patients were asked to report which
injection topics they could not remember ever
being trained in. Table 12 shows that for all
topics, a higher percentage of Indian patients
could not remember being trained than in
ROW, with some percentages sometimes being
2–3 times higher in India.
The Indian HCPs filling out the ITQ were
asked to identify themselves. Table 13 shows
that a much higher percentage of diabetes
educators and specialist doctors filled out the
ITQ forms in India than in ROW. Indian HCPs
were then asked if they were aware that there
were new injection recommendations that had
been published and 94.1% (64 of 68) said yes.
Of these 92.3% (60 of 65) said they had changed




LH is a thickened, ‘‘rubbery’’ lesion that appears
in the subcutaneous (SC) tissue of injecting sites
in up to half of patients who inject insulin. In
some patients the lesions can be hard or scar-like
[4, 5]. Detection of LH requires both visualiza-
tion and palpation of injecting sites, as some
lesions can be more easily felt than seen [6].
Making two ink marks at opposite edges of the
LH (at the junctions between normal and ‘‘rub-
bery’’ tissue) will allow the lesion to bemeasured,
recorded, and followed long-term.
More than a quarter of our Indian patients
described lesions consistent with LH at their
injection sites (Table 1) and approximately 1 in
5 were found to have LH by the examining
nurse (using visual inspection and palpation) at
the time of the ITQ (Tables 1, 2). Figure 1 illus-
trates visible LH in a woman who had injected
in the same two locations below the umbilicus
for 12 years. Figure 2 illustrates the detection of
palpable LH by comparing a fold of normal skin
(arrow tips close together) with lipohyper-
trophic tissue (arrow tips spread apart). Normal
skin can be pinched tightly together, while
lipohypertrophic lesions cannot [7].
LH in India is slightly less frequent than in
ROW (Table 1). This may reflect the fact that
Indian injectors have been using insulin only
5.5 years on average, while patients in ROW
have been using it on average 9.0 years (Table 3
of our first ITQ paper [1]); or it may mean that
intensive therapy with multiple daily injections
(MDI) is still not common in India. (Both time
on insulin and number of injections/day are
known to be risk factors for LH.)
As in ROW, Indian HCPs who examined
injection sites in our study found more LH
lesions by palpation than visually (Table 2),





Routinely every visit 19.6 28.3
Once a year 11.1 12.6
Only if I complain of a
problem at a site
31.7 20.2
I cannot remember my sites
ever being checked
37.6 38.9






Within the past 6 months 42.9 37.4
Within the past 6–12 months 19.4 17.6
Sometime in the last 1–5 years 14.9 21.5





emphasizing the importance of carefully
examining sites with the hands. HCPs should
lubricate their hands before the exam with gel
(ultrasound gel or equivalent) and use a circular
motion, similar to that employed when exam-
ining the breast. LH lesions in India average
about 40 mm, a size which is usually easy to
detect, if one looks for it (Table 3).
Of some consolation is that Indian patients
with LH do not inject into these lesions as fre-
quently as in ROW (Table 4). When asked why
they continued to do so, convenience and pain
were less frequently cited by Indian patients
than those in ROW (Table 5). Most patients
simply did not know why they did so, suggest-
ing that habit or mindlessness is at play.
Upwards of a quarter of Indian patients have
LH. This should probably be considered an
underestimate, since HCPs participating in the
ITQ did not get any special training in LH
detection. The prevalence rates of LH amongst
insulin-injecting patients in other countries





Injection sites (e.g., thigh, arm, buttock, abdomen) 37.7 11.6
Skin thickness and appropriate depth of injection 57.2 27.2
Length of needle 57.2 25.6
How to do a skinlift or ‘‘pinch up’’ the skin 43.6 18.2
How long to hold a skinlift or ‘‘pinch up’’ 49.7 25.7
Angle of needle entry 37.9 16.1
How long to keep the needle in the skin after injection 43.5 16.4
Rotating within an injection site 48.7 18.4
Prevention of air bubbles (syringe) or proper priming of pen needle 52.0 19.7
Mixing insulin in a syringe (for syringe users) 53.2 30.3
Re-suspension of cloudy insulin 55.1 25.0
Single use of pen needle/syringe 61.0 19.0
Safe disposal of sharps (pen needles, syringes) 65.3 28.2





General nurse 9.7 17.1
Diabetes nurse 11.1 56.1
Diabetes educator 63.9 22.8
Doctor (general practitioner) 2.8 1.0
Doctor (specialist) 12.5 3.0
Fig. 1 Two visible lipohypertrophic lesions below the
umbilicus
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varies significantly. In five recent studies it
ranged from lowest to highest: 14.5% (Hajhey-
dari et al. [8]); 27.1% (Raile et al. [9]); 34.5%
(Partanen and Rissanen [10]); 48.0% (Kor-
donouri et al. [11]); 64% (Blanco et al. [12]).
Blanco et al. studied 430 patients from 19
Spanish centers and found that LH was more
common in T1DM (72.3%) than in T2DM
(53.4%). Grassi et al. [13] studied 388 patients
from 18 Italian centers and found a prevalence
of 48.7%. A Chinese study [14] of 401 patients
in four centers found an overall prevalence of
53.1% (95% CI 48.2, 58.0%). By body site, LH
was found in 52.4% of abdomens examined,
15.5% of thighs, and 9.4% of arms.
Lipohypertrophy has also been reported to
be frequent in continuous subcutaneous insulin
infusion (CSII) patients. A cross-sectional study
[15] of 50 consecutive patients with T1DM
using CSII for more than 6 months (26 female;
age, 13.3 ± 3.5 years; CSII duration,
2.8 ± 1.7 years; HbA1c, 7.7% ± 1.1%) examined
the skin for complications associated with
therapy and 42% of these patients had LH. A
similar survey [16] of 91 adult CSII patients
revealed that the commonest infusion site
problem was lipohypertrophy (26.1%),
which occurred more often in those with
long duration of CSII (4.8 [2.38–9.45] vs 3.0
[1.50–4.25] years; p = 0.01).
Vardar and Kizilci [17] identified, by logistic
regression analysis, three independent risk
factors for LH: duration of insulin use, with
longer use associated with more LH (p = 0.001);
site rotation, with a failure to rotate associated
with higher LH risk (p = 0.004); changing nee-
dles, with needle reuse also associated with LH
(p = 0.004). Two other studies [12, 18] have
identified similar factors. Immunologic factors
in LH are poorly understood, although anti-
bodies seem to have a role in pediatric and
adolescent patients with T1DM [9]. Needle
length has not been shown to be a risk factor. It
is also not known what the impact of different
needle lengths is on insulin absorption from
injections into LH.
Histopathologically, LH lesions are shown to
be entirely formed of adipocytes. These cells are
often hypertrophied to two or three times the
size of normal adipocytes. They can be seen
invading the adjacent reticular dermis, engulf-
ing lipid droplets, proliferating or manifesting
other signs of metabolic activation [19]. This
anabolic activity is presumably initiated by
trauma from repeat injections in the same place
and time coupled with the growth-promoting
properties of insulin. There may be genetic
factors but these have not yet been elucidated.
Almost all studies of patients injecting into
LH [20–23] show insulin absorption to be
delayed or erratic, potentially worsening dia-
betes management.
Franzen and Ludvigsson [24] evaluated chil-
dren with diabetes who were injecting into
clinically detectable LH. The children received
simple but direct instructions: rotate injection
sites; and do not reuse your needles. In
3 months 90% of LH lesions in these children
had resolved and were undetectable. HbA1c was
improved significantly and insulin require-
ments had decreased.
Blanco et al. [12] showed that unexplained
hypoglycemia and glycemic variability were
also greatly increased (6- to 7-fold) in those with
versus those without LH. In our study we found
that unexpected hypoglycemia affected more
than a quarter of Indian injecting patients,
while glucose variability was present in over a
third. In both cases, these adverse outcomes
were more common than in ROW (Table 6).
Both have many causes, and injecting into LH is
one of them.
Fig. 2 The different ‘‘pinch’’ characteristics of normal
(left) vs lipohypertrophic (right) tissue
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A critical finding of a Spanish study is the
correlation of total daily dose (TDD) of insulin
to the presence of LH and its derived cost to the
health care system. Subjects with LH had sig-
nificantly higher TDD, overall and in both
T1DM and T2DM groups. T2DM patients had
the highest TDD differences (approximately 20
additional units daily). Such patients tend to
have increased weight and insulin resistance
compared to T1DM patients, and these factors
probably contributed to their greater TDD;
however, the T2DM patients with LH had sim-
ilar weight and BMI as those with T2DM but
without LH. Another major contributor is the
practice of injecting into LH where the absorp-
tion properties of insulin are distorted. The cost
of the additional insulin consumed by injecting
into LH was calculated (based on prevalence of
LH, number of insulin-injecting patients in
Spain, differences in TDD, and the cost in Euros
per unit of insulin) to be over 122 million euros
in Spain. This is an obvious opportunity for
savings to both patients and health care payers.
The one weakness of the Spanish study is that
HbA1c levels were unfortunately not collected
from the subjects examined. A Chinese study
similar to the Spanish one showed remarkably
similar results,1 with the addition that patients
with LH had significantly higher HbA1c values
(8.2 ± 1.8) than those without LH (7.7 ± 1.5)
(p\0.003) [14, 25]
The impact of LH on insulin PK-PD is rather
poorly documented in the literature. While
there are case reports indicating reductions in
insulin consumption with improvements in
HbA1c when patients with LH were taught to
inject into normal areas, and a small number of
studies that evaluated insulin PK-PD when
patients injected into areas of LH vs normal
areas, the overall quality of such studies is poor
and/or they were substantially underpowered. It
is assumed that LH reduces and/or slows insulin
uptake, and perhaps increases PK-PD variation,
but this has not been proven rigorously.
Two closely related studies have addressed
these questions, using state-of-the-art method-
ologies. A glucose clamp study [26] in patients
with LH has shown that both insulin absorption
and action are substantially blunted and con-
siderably more variable when insulin is injected
into areas with LH.2 A separate, mixed meal
study in the same subjects confirmed the slower
absorption and decreased action of insulin
when injected into LH compared to normal
adipose tissue, with much greater post-meal
glycemic excursions shown [27].
Site Rotation
Several studies have demonstrated that the best
way to safeguard normal tissue is to properly
and consistently rotate injecting sites [28–30].
Injection can be rotated from one body region
to another (abdomen to thigh, to buttock, to
arm) but it must be remembered that absorp-
tion characteristics change depending on the
1 Specifically, LH was present in 52.9% of participants.
Patients were an average of 59.6 (SD = 11.5) years old
and took insulin for 5.6 (SD = 4.6) years, averaging 33.0
(SD = 18.4) U/day. HbA1c was 8.2% (1.8) and 7.7% (1.5),
respectively, in those with and without LH (p = 0.003).
LH was associated with higher daily insulin dose (38.1 vs
27.1 U, p\0.001) and cost [the Chinese currency, the
Renminbi (RMB 8.2 vs 5.8, p\0.001)]. Those with LH
averaged 2.3 (2.2) nodes, had higher frequency of pen
needle (PN) reuse (median 13.0 vs 7.5, p = 0.003), and
greater total 6-month direct costs (RMB 5506.9 vs
5258.0, p = 0.037). With 8.4 million insulin injectors
in China, the estimated excess annual direct cost of LH is
RMB 2.2 billion ($360 million). Average pain scores
(0–10) were higher if LH was present (2.7 vs 2.0,
p = 0.021), if C3 nodes were present (3.8 vs 2.3,
p\0.001), and if PNs were not reimbursed (2.8 vs 1.7,
p\0.001). Patient satisfaction decreased as presence,
number, and size of LH nodes increased (all p\0.05).
2 Specifically the study investigated insulin exposure and
pharmacodynamics of insulin lispro injected into abdom-
inalareaswithLHornormal adipose tissue.ThirteenT1DM
with LH (confirmed by palpation and ultrasound) received
single doses of 0.15 U/kg LIS approximately every 6 h,
twice into a regionwith LHT and twice into normal tissue.
Comparing LHT with NAT injection, LS-mean INS con-
centrations were comparable during the first 30 min
(AUCINS0–0.5 h 8.8 vs 9.4 h mU/L), but significantly
lower thereafter (AUCINS0–1 h 29.3 vs 41.5 h mU/L,
AUCINS.0–4 h 97 vs 154 h mU/L, all p\0.02). Maximum
INS exposure was reduced by 34% (CINSmax 49.7 vs
75.4 mU/L, p\0.002). The PD effect in the first 4 h was
27% lower with LHT injection (AUCGIR0–4 h: 529 vs
720 mg/kg, p\0.05), whereas maximumGIR was compa-
rable (GIRmax 5.5 vs 6.0 mg/kg/min, p = 0.378). Intrasub-
ject variability was substantially higher after dosing into
LHT (coefficients of variation 52% vs 11% [AUCINS.0–4 h]
and 57% vs 23%, [AUCGIR0–4 h], all p\0.002).
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type of insulin given. Analogues can be given at
any injection site with similar uptake and
action (PK-PD), but human insulins (regular,
NPH) vary substantially—absorption being
fastest from the abdomen and slowest from the
buttock. However, correct rotation involves
spacing injections a least 1 cm. apart even
within an injection zone. Table 8 shows that
68.1% of Indian injectors were found to cor-
rectly rotate site, a value similar to ROW. This
may be why the LH rate in India is lower than in
ROW (Table 1).
Some clinicians are offering the single-use
skin safe marker pen to patients to keep and use
to make a dot on the skin where they inject and
use this as a reference point for the next injec-
tion. This seems to work very well for some
patients and the marker from the pen washes
off and fades to nothing in about 5 days.
One scheme with proven effectiveness
involves dividing the injection site into quad-
rants (or halves when using the thighs or but-
tocks), using one quadrant per week and
moving always clockwise, as shown by Figs. 3
and 4 [7]. Injections within any quadrant or half
should be spaced at least 1 cm from each other
in order to avoid repeat tissue trauma. Pump
cannulae should be placed at least 3 cm away
from previous sites. HCPs should verify that the
rotation scheme is being followed at each visit
and give help and advice where needed.
Lipoatrophy
Lipoatrophy (LA) has been reported in all
injecting sites [31–36]. It is now considered a
relatively unusual condition, prompting case
reporting. Risk factors are not understood. Some
authors have suggested that young women with
other autoimmune disorders may be at higher
risk. LA is felt to be a local immune reaction
against fat cells provoked by insulin crystals.
Consequently LA is rarer today than it was
when less pure insulins were given. But LA is
still observed even with short- and long-acting
analogues. LA causes significant variability in
insulin absorption when injections are given
into it.
Treatment for LH is not evidence-based
because of the lack of trials. Several approaches,
however, have been recommended: changing
the insulin formulation (e.g., aspart to lispro, or
lispro to glulisine, etc.), changing injection
sites, or shifting to CSII and possibly cortisone
injected into the LA. LA may or may not resolveFig. 3 Abdominal rotation pattern by quadrants
Fig. 4 Thigh and buttocks rotational pattern by halves
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with time, but this depends on the individual
patient. LA has been seen with the short-acting
analogues, lispro and aspart, as well as the
long-acting ones, glargine and detemir. It may
also be associated with non-rotation of injec-
tion sites and needle reuse. LA is both a cos-
metic problem (disfiguring) and a clinical one
(erratic and abnormal insulin absorption).
Fortunately lipoatrophy is now much less
common than it used to be in the days of ani-
mal insulins. In our study it affected only about
2% of Indian injectors, a figure compatible with
ROW (Table 7).
Injection Pain
We found that just over half of Indian injectors
report having pain on injection. Of these, 4 out
of 5 report having painful injections only sev-
eral times a month or year (i.e., not with every
injection).
As the above data suggests, most insulin
injections are not painful, except in the infre-
quent event that the needle comes into direct
contact with a nerve ending. Some patients,
however, are exceptionally sensitive to sensa-
tions they describe as painful. Patient awareness
of injection discomfort has been studied
extensively and is related to three key factors:
needle length (and tissue level penetrated);
needle diameter; and injection context. Injec-
tion context is defined by environment (in-
cluding noise and the presence of other people),
view of the needle, and the apprehension of
HCPs, both professional and family. The more
apprehension the latter display, the greater the
pain and anxiety felt by the patient [37, 38].
This reverse transference places a large respon-
sibility on carers to assess their own attitudes
towards injection pain. Some patients complain
of discomfort when injecting insulins which
have a low pH. This seems, anecdotally, to be
reported more commonly in children. Glargine
is an example of an acidic insulin.
Heise et al. [39] showed that injection speed
(150, 300, and 450 ll/s; equivalent to 15–45 IU/s
of U100 insulin) makes no difference in pain. But
injection volume does, with higher volumes
(C1200 ll or 120 IU of U100 insulin) causing
more pain. His group also found that injections
in the thigh appear to hurt more than those in
the abdomen in adults. Anderson et al. [40] and
Jorgensen et al. [41] also found that higher
injected volumes cause more pain. Hofman et al.
[42] as well showed in both children and adults
that thigh injections are more painful than
abdominal ones. Nevertheless, Heise et al. [39]
found that most patients say the pain is accept-
able regardless of volume or injection site. So we
can reasonably conclude that injection pain,
though felt under certain circumstances by cer-
tain patients, is mild enough to be acceptable to
most of them, particularly with today’s very
thin, short needles.
This survey shows that at present injection
training in India is performed mainly by dia-
betes educators and physicians (Table 9).
Despite this specialized approach, a very high
percentage of patients report that they have not
been trained (at least cannot remember being
trained) in a wide range of essential injection
topics (Table 12).
The latest version of the Indian insulin
injection recommendations (from 2015 [43])
has specific guidelines for each one of these
topics, and many others.
We know that injecting training works, even
when delivered only one time. In a recent Ital-
ian study [13], 346 patients with diabetes from
18 ambulatory centers throughout northern
Italy who had been injecting insulin for at least
4 years received a thorough evaluation of their
injection technique (IT). Their doctors and
nurses then examined all injection sites for the
presence of LH, followed by an individualized
training session in which suboptimal IT prac-
tices were addressed. All patients were taught to
rotate sites correctly in order to avoid LH and
were begun on 4-mm pen needles to increase
potential injection sites, while avoiding intra-
muscular (IM) injections. Patients were also
instructed not to reuse needles. Results showed
that 49% of patients had LH at study entry.
After 3 months, patients had mean reductions
in HbA1c of 0.58%, in fasting blood glucose of
14 mg/dL, and in total daily insulin dose of
2.0 IU (from baseline 50.5 IU), all statistically
significant at p\0.05. Follow-up questionnaires
showed that significant numbers of patients
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recognized the importance of IT and were per-
forming their injections more optimally. The
majority found the 4-mm pen needle conve-
nient and comfortable.
The relationship between diabetes education
and glucose control is far from simple. A recent
study suggested that education alone (including
empowerment) may not be sufficient to ensure
behavioral change and improved glycemic
control, at least in T2DM patients managed in
primary care [44].
Therapeutic Education
It is clear that ‘‘education’’, defined as the simple
imparting of information, is not enough. In
diabetes we must employ ‘‘therapeutic educa-
tion’’ [45]. Therapeutic education is above all
patient-centered, focusing on individual needs,
resources, and values. It tailors individual
strategies to the patient, and the individual
patient helps shape these strategies. Patients
participate actively in their treatment, eventu-
ally virtually taking it over. Therapeutic educa-
tion takes into account a whole array of
psychological, social, and biologic factors. It
tackles the hardest things human beings must
do—change behavior. It uses the approaches
and brings to bear all power of cognitive
behavioral therapy. It focuses on motivation,
step-by-step change, and compassion with
oneself in the face of failure. Injection training
must be rooted in therapeutic education to be
effective.
Studies have shown that not all patients
receive therapeutic education about injections
and for those who do, not all critical topics are
covered [46–48]. This was very clear from our
study (Table 12). One principle of therapeutic
education is that decisions should be made in a
discussion context in which the patient is a
partner and the HCP offers experience and
advice [49, 50]. Therapeutic education can also
occur in a group setting, and there is evidence
that lower subsequent HbA1c values and better
adherence are achieved if the HCP has formal
training as an educator [6].
Educational guidelines for injectors rec-
ommend checking injection sites at least
annually and more frequently when the risk
for LH or other complication is high. Our
study showed that only about 30% of Indian
injectors get their sites checked this frequently
(Table 10), with nearly a third only having
sites checked when they specifically com-
plained and nearly 4 out of 10 never having
had their sites checked. This is clearly an area
in which therapeutic education in India can
be improved.
Conversely, India is doing a somewhat better
job than ROW in giving advice about injections.
Nearly two-thirds of injecting patients had been
given instruction in the last year (Table 11). But
Indian HCPs can clearly do a better job covering
all the vital topics essential to proper injection
habits (Table 12).
CONCLUSIONS
The first Indian insulin injection technique
recommendations were published in Indian
Journal of Endocrinology & Metabolism, November
2012 issue. Addenda were published in the
November 2013 and November 2014 issues of
that journal. The latest version of these recom-
mendations were published in 2015 [43]. That
version provides the following guidelines for
preventing LH:
• Regular inspection and palpation of insulin
sites
• Do not reuse needles
• Follow correct site rotation policy
• Use larger injection surface areas
• Do not inject into LH sites
• Reduce dose of insulin in habitual LH site
injections when shifting to normal SC tissue
• Rule out LH as a cause of poor glycemic
control, hypoglycemia, and high glycemic
variability
Before starting the injection therapy, the
healthcare provider should ensure that patients
understand each of these essential topics:
• The injection regimen
• The choice and management of the devices
used
• The choice, care, and self-examination of the
devices used
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• Proper injection techniques (including site
rotation, injection angle, and possible use of
skinfolds)
• Injection complications and how to avoid
them
• Optimal needle lengths
• Safe disposal of used sharps [6, 49–55]
• Healthcare professionals should spend ample
time exploring patient anxieties and other
concerns about the injecting process and
insulin itself.
A quality management process should be put in
place and make sure that the correct injection tech-
nique has been practiced regularly by patients and is
also documented in the record.
All results from the ITQ survey data are avail-
able in an interactive form on Tableau Public
AdamYoung’s Profilewebsite [56].Webelieve the
latest ITQ data support and reinforce the above
recommendations. Every diabetes center in India
shouldbe familiarwith the ITQ results and should
be scrupulous in following the official Indian
insulin injection recommendations.
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